Peking University Biologics

Company snapshot

Peking University Biologics is a one-stop biopharmaceutical CDMO professional organization with many years of biopharmaceutical scale-up, optimization, and technology transfer experience focusing on biologic drugs from gene development to CMC preparation, IND application, commercial manufacturing, BLA to commercialization. In 2021, we were the first leading biologics CDMO company to obtain the “Dr

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Peking University Biologics. Not investment advice.

• What is Peking University Biologics?

  Peking University People's is a pharma organization headquartered in CN. Primary therapeutic focus areas include Adenocarcinoma of Lung, Primary Sjögren's Syndrome. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FD

• Is Peking University Biologics publicly traded?

  Peking University Biologics appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Peking University Biologics develop or market?

  We link 2 drug profile(s) where Peking University Biologics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/peking-university-people-s-hospital#company-drugs.

• What are the latest developments for Peking University Biologics?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Peking University Biologics focus on?

  Peking University Biologics focuses on Adenocarcinoma of Lung, Primary Sjögren's Syndrome based on our analysis of their pipeline programs and drug development activities.